What the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.88%
Annual Rate
CNY 1.20Paid semi-annual
Payout Ratio
36.6%Sustainable
Last Ex-Dividend
Jun 10, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
22.58BCNY
3.36B · vs all stocks (USD)
Updated Aug 21, 2026
Trailing P/E
98.33x
vs Scientific & Technical Instruments peers
Updated Aug 21, 2026
Revenue (TTM)
1.17BCNY
174.64M · vs all stocks (USD)
Updated Aug 21, 2026
Profit Margin
15.74%
vs Scientific & Technical Instruments peers
Updated Aug 21, 2026
Beta
2.57x
vs all stocks
Updated Aug 21, 2026
52-Week Change
128.27%
vs all stocks
Updated Aug 21, 2026
Forward Annual Dividend Yield
0.88%
vs all stocks
Updated Aug 21, 2026
Market Capitalization
22.58BCNY
3.36B · vs all stocks (USD)
Updated Aug 21, 2026
Enterprise Value
22.56BCNY
3.35B · vs all stocks (USD)
Updated Aug 21, 2026
Trailing P/E
98.33x
vs Scientific & Technical Instruments peers
Updated Aug 21, 2026
Forward P/E
40.04x
vs Scientific & Technical Instruments peers
Updated Aug 21, 2026
Price to Sales (TTM)
18.86x
vs Scientific & Technical Instruments peers
Updated Aug 21, 2026
Price to Book (MRQ)
6.56x
vs Scientific & Technical Instruments peers
Updated Aug 21, 2026
Enterprise to Revenue
19.21x
vs Scientific & Technical Instruments peers
Updated Aug 21, 2026
Enterprise to EBITDA
119.60x
vs Scientific & Technical Instruments peers
Updated Aug 21, 2026
Gross Margin
42.88%
vs Scientific & Technical Instruments peers
Updated Aug 21, 2026
Profit Margin
15.74%
vs Scientific & Technical Instruments peers
Updated Aug 21, 2026
Operating Margin
12.58%
vs Scientific & Technical Instruments peers
Updated Aug 21, 2026
Return on Assets (TTM)
2.43%
vs Scientific & Technical Instruments peers
Updated Aug 21, 2026
Return on Equity (TTM)
5.37%
vs Scientific & Technical Instruments peers
Updated Aug 21, 2026
Revenue (TTM)
1.17BCNY
174.64M · vs all stocks (USD)
Updated Aug 21, 2026
Revenue per Share (TTM)
7.19CNYUpdated Aug 21, 2026
Quarterly Revenue Growth
48.30%
vs Scientific & Technical Instruments peers
Updated Aug 21, 2026
Gross Profit (TTM)
512.27MCNY
76.18M · vs all stocks (USD)
Updated Aug 21, 2026
EBITDA (TTM)
185.33MCNY
27.56M · vs all stocks (USD)
Updated Aug 21, 2026
Net Income (TTM)
184.87MCNY
27.49M · vs all stocks (USD)
Updated Aug 21, 2026
Quarterly Earnings Growth (YoY)
25.00%
vs Scientific & Technical Instruments peers
Updated Aug 21, 2026
Operating Cash Flow (TTM)
189.02MCNY
28.11M · vs all stocks (USD)
Updated Aug 21, 2026
Levered Free Cash Flow (TTM)
-41.93MCNY
-6.24M · vs all stocks (USD)
Updated Aug 21, 2026
Forward Annual Dividend Rate
1.20CNYUpdated Aug 21, 2026
Forward Annual Dividend Yield
0.88%
vs all stocks
Updated Aug 21, 2026
Trailing Annual Dividend Rate
1.01CNYUpdated Aug 21, 2026
Trailing Annual Dividend Yield
0.74%
vs all stocks
Updated Aug 21, 2026
Payout Ratio
36.62%
vs Scientific & Technical Instruments peers
Provider-reported. Trailing Annual Dividend Rate ÷ Diluted EPS (TTM) on this page gives 74.54%.Updated Aug 21, 2026
Minority Interest (Equity)
42.56MCNYFY2025 · Dec 31, 2025
Revenue
1.08BCNYFY2025 · Dec 31, 2025
Cost of Goods Sold
600.61MCNYFY2025 · Dec 31, 2025
Gross Profit
477.32MCNYFY2025 · Dec 31, 2025
Operating Income
160.65MCNY
23.89M · vs all stocks (USD)
FY2025 · Dec 31, 2025
Pre-tax Income
192.15MCNYFY2025 · Dec 31, 2025
Income Tax Expense
18.42MCNYFY2025 · Dec 31, 2025
Net Income
173.73MCNYFY2025 · Dec 31, 2025
EBIT
194.96MCNYFY2025 · Dec 31, 2025
EBITDA (Income Statement)
222.75MCNYFY2025 · Dec 31, 2025
Research & Development
115.80MCNYFY2025 · Dec 31, 2025
Selling, General & Administrative
66.39MCNYFY2025 · Dec 31, 2025
Other Operating Expenses
10.04MCNYFY2025 · Dec 31, 2025
Non-operating Interest Income
11.60MCNYFY2025 · Dec 31, 2025
Non-operating Interest Expense
2.81MCNYFY2025 · Dec 31, 2025
EPS (Basic)
1.07CNYFY2025 · Dec 31, 2025
EPS (Diluted)
1.07CNYFY2025 · Dec 31, 2025
Basic Shares Outstanding
164.52MSharesFY2025 · Dec 31, 2025
Diluted Shares Outstanding
164.52MSharesFY2025 · Dec 31, 2025
Net Income from Continuing Operations
173.73MCNYFY2025 · Dec 31, 2025
Minority Interests (P&L)
2.31MCNYFY2025 · Dec 31, 2025
Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025
Operating Cash Flow
-12.90MCNYFY2025 · Dec 31, 2025
Free Cash Flow
-346.54MCNYFY2025 · Dec 31, 2025
Cash & Cash Equivalents (End of Period)
309.59MCNYFY2025 · Dec 31, 2025
Starting Profit (CF Statement)
173.73MCNYFY2025 · Dec 31, 2025
Other Non-cash Items
8.01MCNYFY2025 · Dec 31, 2025
Change in Accounts Receivable (CF)
-157.42MCNYFY2025 · Dec 31, 2025
Change in Other Assets/Liabilities
-37.23MCNYFY2025 · Dec 31, 2025
Capital Expenditures
-333.64MCNYFY2025 · Dec 31, 2025
Net Acquisitions
-89.39MCNYFY2025 · Dec 31, 2025
Purchase of Investments
-5.67BCNYFY2025 · Dec 31, 2025
Sale of Investments
6.09BCNYFY2025 · Dec 31, 2025
Other Investing Activity
-11.02MCNYFY2025 · Dec 31, 2025
Net Investing Cash Flow
-13.24MCNYFY2025 · Dec 31, 2025
Long-term Debt Issuance
84.95MCNYFY2025 · Dec 31, 2025
Common Dividends Paid
-70.58MCNYFY2025 · Dec 31, 2025
Other Financing Charges
23.10MCNYFY2025 · Dec 31, 2025
Net Financing Cash Flow
37.48MCNYFY2025 · Dec 31, 2025
Shares Outstanding
165.59MSharesUpdated Aug 21, 2026
Float Shares
102.22MSharesUpdated Aug 21, 2026
% Held by Insiders
40.30%
vs all stocks
Updated Aug 21, 2026
% Held by Institutions
9.85%
vs all stocks
Updated Aug 21, 2026
Total Cash (MRQ)
1.23BCNY
182.98M · vs all stocks (USD)
Updated Aug 21, 2026
Total Cash per Share (MRQ)
7.52CNYUpdated Aug 21, 2026
Total Debt (MRQ)
192.66MCNY
28.65M · vs all stocks (USD)
Updated Aug 21, 2026
Total Debt to Equity (MRQ)
0.0550x
vs Scientific & Technical Instruments peers
Updated Aug 21, 2026
Current Ratio (MRQ)
2.91x
vs Scientific & Technical Instruments peers
Updated Aug 21, 2026
Book Value per Share (MRQ)
20.40CNYUpdated Aug 21, 2026
Total Assets
4.10BCNY
609.16M · vs all stocks (USD)
FY2025 · Dec 31, 2025
Total Current Assets
2.37BCNYFY2025 · Dec 31, 2025
Total Liabilities
679.76MCNYFY2025 · Dec 31, 2025
Total Non-current Assets
1.73BCNYFY2025 · Dec 31, 2025
Total Non-current Liabilities
86.81MCNYFY2025 · Dec 31, 2025
Total Current Liabilities
592.95MCNYFY2025 · Dec 31, 2025
Cash
309.37MCNYFY2025 · Dec 31, 2025
Cash Equivalents
24.94MCNYFY2025 · Dec 31, 2025
Cash & Cash Equivalents
334.31MCNYFY2025 · Dec 31, 2025
Other Short-term Investments
1.16BCNYFY2025 · Dec 31, 2025
Accounts Receivable
358.37MCNYFY2025 · Dec 31, 2025
Inventory
305.71MCNYFY2025 · Dec 31, 2025
Accounts Payable
326.45MCNYFY2025 · Dec 31, 2025
Short-term Debt
51.69MCNYFY2025 · Dec 31, 2025
Other Current Liabilities
32.71MCNYFY2025 · Dec 31, 2025
Long-term Debt
75.44MCNYFY2025 · Dec 31, 2025
Other Non-current Liabilities
1.09MCNYFY2025 · Dec 31, 2025
Common Stock (Book)
165.59MCNYFY2025 · Dec 31, 2025
Retained Earnings
272.89MCNYFY2025 · Dec 31, 2025
Total Shareholders' Equity
3.42BCNY
508.07M · vs all stocks (USD)
FY2025 · Dec 31, 2025
Treasury Stock
74.12MCNYFY2025 · Dec 31, 2025
52-Week Low
55.70CNYUpdated Aug 21, 2026
52-Week High
215.00CNYUpdated Aug 21, 2026
52-Week Change
128.27%
vs all stocks
Updated Aug 21, 2026
Beta
2.57x
vs all stocks
Updated Aug 21, 2026
50-Day MA
150.49CNYUpdated Aug 21, 2026
200-Day MA
102.56CNYUpdated Aug 21, 2026
Avg 10-Day Volume
5.57MSharesUpdated Aug 21, 2026
Avg 30-Day Volume
6.22MSharesUpdated Aug 21, 2026
Diluted EPS (TTM)
1.36CNYUpdated Aug 21, 2026
3 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Operating Income Growing With Multi-Year Revenue Growth
Revenue up in each of five years, with operating income up in each of four.
Reads
Is this company growing?
Multi-Year Revenue And Profit Growth
Revenue and earnings have both grown steadily across six years.
Reads
Multi-Year Revenue, Profit, And Income Growth
Revenue has risen in each of three years, gross profit in each of four, and it has made a profit in all five.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.